<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724928</url>
  </required_header>
  <id_info>
    <org_study_id>86702020000105</org_study_id>
    <nct_id>NCT04724928</nct_id>
  </id_info>
  <brief_title>Evaluating the Impact of FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer</brief_title>
  <acronym>EFFORT-MIBC</acronym>
  <official_title>Phase II Prospective Trial to Evaluate the Impact of 18F-FDG-PET-CT in Stratifying Patients With Muscle Invasive Bladder Cancer and Tailoring the Treatment Accordingly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive&#xD;
      bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in&#xD;
      non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment&#xD;
      is adapted accordingly to improve overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only patients presenting with non-metastatic MIBC on conventional CT scan are eligible for&#xD;
      the trial.&#xD;
&#xD;
      Additionally, 2 18F FDG-PET-CT scans per patient will be performed, prior and after&#xD;
      neo-adjuvant chemotherapy. All patients will have a radical treatment to the bladder either&#xD;
      by radical cystectomy or trimodality therapy.&#xD;
&#xD;
      In case of diagnosis of oligometastatic disease on 1 of both FDG-PET-CT's, a metastasis&#xD;
      directed therapy to the oligometastatic sites will be added.&#xD;
&#xD;
      In case of polymetastatic disease on FDG-PET-CT, additional immunotherapy will be&#xD;
      administered (this is standard of care after chemotherapy failure)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>24 months</time_frame>
    <description>2-years overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Muscle-Invasive Bladder Carcinoma</condition>
  <condition>Oligometastatic Disease</condition>
  <arm_group>
    <arm_group_label>non-metastatic MIBC on PET-CT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients receive classical treatment with neo-adjuvant chemotherapy followed by radical cystectomy (RC) or trimodality therapy (TMT) and regular follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oligo-metastatic MIBC on PET-CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive classical treatment with neo-adjuvant chemotherapy followed by RC or trimodality therapy TMT and metastasis-directed therapy followed by regular follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>poly-metastatic MIBC on PET-CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive classical treatment with neo-adjuvant chemotherapy followed by RC or trimodality therapy TMT and start of immunotherapy followed by regular follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>metastasis directed therapy (MDT)</intervention_name>
    <description>MDT in case of oligometastases</description>
    <arm_group_label>oligo-metastatic MIBC on PET-CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>immunotherapy in the setting of polymetastatic disease</description>
    <arm_group_label>poly-metastatic MIBC on PET-CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - newly diagnosed MIBC with no signs of metastasis on conventional imaging (i.e. CT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extra-pelvic metastasis (M1 disease) on conventional imaging (CT thorax/abdomen/MRI)&#xD;
&#xD;
          -  Prior RT enabling MDT&#xD;
&#xD;
          -  Contra-indication for 18F FDG PET-CT&#xD;
&#xD;
          -  Contraindications to radiotherapy (including active inflammatory bowel disease)&#xD;
&#xD;
          -  No prior Cisplatin-based chemotherapy in the neo-adjuvant setting&#xD;
&#xD;
          -  Patient refusing 18F FDG PET-CT&#xD;
&#xD;
          -  Patient refusing MDT or immunotherapy&#xD;
&#xD;
          -  Other primary tumour diagnosed &lt;5 years ago and for which treatment is still required&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET-CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

